Tamara Maes

Barcelona, CT, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

Phenotype and psychometric characterization of Phelan-McDermid syndrome patients: pioneering towards personalized medicine.

Phenotype and psychometric characterization of Phelan-McDermid syndrome patients: pioneering towards personalized medicine.

Journal: Frontiers in psychiatry

Published: October 15, 2024

Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis.

Journal: Pharmaceutics

Published: June 03, 2022

Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology.

Comprehensive in Vitro Characterization of the LSD1 Small Molecule Inhibitor Class in Oncology.

Journal: ACS pharmacology & translational science

Published: September 22, 2021

First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.

First-in-Human Randomized Trial to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the KDM1A Inhibitor Vafidemstat.

Journal: CNS drugs

Published: February 12, 2021

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

First-in-Human Phase I Study of Iadademstat (ORY-1001): A First-in-Class Lysine-Specific Histone Demethylase 1A Inhibitor, in Relapsed or Refractory Acute Myeloid Leukemia.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 14, 2020

Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations.

Modulation of KDM1A with vafidemstat rescues memory deficit and behavioral alterations.

Journal: PloS one

Published: January 09, 2020

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays.

Direct Measurement of KDM1A Target Engagement Using Chemoprobe-based Immunoassays.

Journal: Journal of visualized experiments : JoVE

Published: July 02, 2019

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.

Pre-clinical activity of combined LSD1 and mTORC1 inhibition in MLL-translocated acute myeloid leukaemia.

Journal: Leukemia

Published: February 12, 2019

Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors.

Chemoprobe-based assays of histone lysine demethylase 1A target occupation enable in vivo pharmacokinetics and pharmacodynamics studies of KDM1A inhibitors.

Journal: The Journal of biological chemistry

Published: December 05, 2018

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.

ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia.

Journal: Cancer cell

Published: May 19, 2017

Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.

Understanding Epigenetic Alterations in Alzheimer's and Parkinson's Disease: Towards Targeted Biomarkers and Therapies.

Journal: Current pharmaceutical design

Published: January 26, 2017

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.

KDM1 histone lysine demethylases as targets for treatments of oncological and neurodegenerative disease.

Journal: Epigenomics

Published: June 26, 2015

Showing 1-12 of 13

Last Updated: 09/26/2026